U.S. Wireless Telecom Stock News

NYSE:LYB
NYSE:LYBChemicals

Will Strong Q1 Beat and Tighter Supply Dynamics Shift LyondellBasell’s (LYB) Long-Term Narrative?

LyondellBasell Industries N.V. has released its first-quarter 2026 results, reporting revenue of US$7,197 million and net income of US$123 million, with adjusted earnings per share from continuing operations of US$0.49 coming in ahead of analyst expectations. Management highlighted that tighter global petrochemical supply linked to Middle East disruptions, combined with operational discipline and increased production, is supporting stronger pricing and an expected sequential improvement in...
NYSE:LHX
NYSE:LHXAerospace & Defense

L3Harris (LHX) Narrows 2026 EPS Guidance Is Management Signaling Greater Confidence in Its Execution?

L3Harris Technologies recently reported first-quarter 2026 results showing sales of US$5,744 million and net income of US$512 million, while also modestly raising its full-year 2026 revenue and diluted EPS guidance. The combination of higher quarterly earnings per share and tighter, upgraded EPS guidance highlights management’s confidence in the company’s operating performance and outlook. Next, we’ll explore how this upgraded 2026 earnings guidance may affect L3Harris’s existing investment...
NasdaqGS:AGYS
NasdaqGS:AGYSSoftware

Agilysys (AGYS) Is Up 13.8% After Unveiling 30+ New AI Features Across Hospitality Platforms

Agilysys, Inc. recently unveiled more than 30 new AI-powered features and software modules at its April 20–23, 2026 INSPIRE user conference, many of which are in early release and slated for initial customer deployments within about 90 days, while also announcing plans to release its fiscal 2026 fourth-quarter results on May 18, 2026. The breadth of these AI-native enhancements, spanning guest personalization, agentic automation, and revenue intelligence across its PMS, POS, and reservations...
NYSE:DFIN
NYSE:DFINCapital Markets

Is Donnelley Financial Solutions (DFIN) Pricing Look Attractive After Recent Share Price Weakness

Wondering if Donnelley Financial Solutions at around US$44 is offering value or just noise? This article breaks down what the current price might actually mean for you. The stock recently closed at US$44.21, with returns of a 12.1% decline over 7 days, a 10.0% decline over 30 days and a 3.1% decline year to date, alongside a 17.2% decline over 1 year, a 0.2% decline over 3 years and a 73.6% gain over 5 years. Recent coverage of Donnelley Financial Solutions has focused on its role in...
NYSE:FND
NYSE:FNDSpecialty Retail

A Look At Floor & Decor (FND) Valuation After Earnings, 2026 Guidance, Store Expansion And Buyback

Floor & Decor Holdings (FND) has come into focus after releasing first quarter results, issuing full year 2026 guidance, outlining plans for 20 new warehouse stores, and announcing a new US$400 million share repurchase program. See our latest analysis for Floor & Decor Holdings. The recent earnings release, new 2026 guidance, planned 20 warehouse openings and US$400 million buyback have coincided with short term momentum, with a 7 day share price return of 6.45% and 1 month share price return...
NasdaqGS:CGNT
NasdaqGS:CGNTSoftware

Why Cognyte Software (CGNT) Is Up 17.9% After Securing A US$20M AI Analytics Subscription Deal

Cognyte Software Ltd. previously announced a three-year subscription contract worth over US$20,000,000 with a long-standing EMEA-region customer, expanding deployment of its AI-driven analytics to handle higher data volumes and more complex investigations. The shift of this long-term relationship to a subscription model underscores recurring revenue visibility and deeper integration of Cognyte’s capabilities into mission-critical operations. Next, we’ll explore how this expanded, multi-year...
NYSE:AFL
NYSE:AFLInsurance

How Investors Are Reacting To Aflac (AFL) Earnings Miss Amid PFML Expansion And Capital Returns

Aflac Incorporated recently reported first-quarter 2026 results, with revenue rising to US$4.35 billion and net income to US$1.02 billion, while also continuing share repurchases, maintaining its quarterly dividend, and opening a new claims office in South Portland to support Maine’s Paid Family and Medical Leave program that began paying benefits on May 1. Despite this combination of earnings growth, capital returns, and expansion into state-administered leave programs, management...
NYSE:ACM
NYSE:ACMConstruction

Is AECOM (ACM) Pricing Reflect Its Value After Recent Share Price Weakness

If you are wondering whether AECOM's share price reflects its true value, you are not alone. This article focuses squarely on what the current price might be asking you to pay. The stock last closed at US$81.47, with returns of a 3.1% decline over 7 days, 2.2% decline over 30 days, 15.5% decline year to date and 21.1% decline over the past year, set against longer term returns of 7.8% over 3 years and 26.4% over 5 years. Recent coverage has centered on how investors are reassessing...
NYSE:ABBV
NYSE:ABBVBiotechs

Is AbbVie (ABBV) Still Worth Considering After Recent Share Price Pullback?

Investors may be wondering if AbbVie at around US$202 a share still offers value, or if most of the opportunity has already played out. The stock has recently seen mixed returns, with a 4.1% decline over the last 7 days, a 1.8% decline over 30 days, and an 11.6% decline year to date. Over 1 year and 5 years, the returns stand at 12.8% and 109.7% respectively. Recent headlines have focused on AbbVie's position in the large-cap pharmaceuticals space and how investors are weighing its long term...
NasdaqGS:LITE
NasdaqGS:LITECommunications

What Lumentum Holdings (LITE)'s AI-Fueled Q3 Beat and NVIDIA Deal Means For Shareholders

Lumentum Holdings Inc. reported past fiscal third-quarter 2026 results with sales rising to US$808.4 million and net income to US$144.2 million, alongside strong guidance calling for fourth-quarter net revenue between US$960 million and US$1.01 billion. The surge in profitability was driven largely by demand for AI and cloud-related optical components, supported by expanded manufacturing capacity and a multiyear US$2.00 billion preferred equity investment and supply agreement with...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

Is It Time To Revisit DraftKings (DKNG) After Recent Share Price Rebound

If you are trying to work out whether DraftKings stock looks attractively priced or too expensive at today’s levels, you will want more than just the latest share price in front of you. The stock recently closed at US$25.22, with returns of 8.1% over 7 days and 9.9% over 30 days, while year to date and 1 year returns of negative 29.3% and negative 28.7% show a very different picture over a longer window. Recent headlines around DraftKings have largely focused on the broader US sports betting...
NYSE:DECK
NYSE:DECKLuxury

How Investors May Respond To Deckers Outdoor (DECK) Analyst Upgrade Backed By HOKA And UGG

Earlier this week, Bernstein analyst Aneesha Sherman upgraded Deckers Outdoor to a hold rating, reflecting greater confidence in the company’s operating profile and brand positioning. This shift in analyst stance comes as Deckers’ core brands, particularly HOKA and UGG, continue to underpin strong fundamentals and attract growing investor attention. We’ll now examine how this improved analyst sentiment, anchored in the strength of HOKA and UGG, reshapes Deckers Outdoor’s investment...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Johnson And Johnson IBD Trial Wins Contrast With Valuation And Momentum

Johnson & Johnson (NYSE:JNJ) reported positive Phase 2b results for its investigational co antibody therapy JNJ-4804 in highly refractory ulcerative colitis and Crohn's disease. The company also released positive Phase 3 data for TREMFYA in perianal fistulizing Crohn’s disease, a difficult form of inflammatory bowel disease. Johnson & Johnson plans to advance JNJ-4804 and related programs into Phase 3 trials to address high unmet needs in inflammatory bowel diseases. For investors tracking...
NYSE:SEI
NYSE:SEIEnergy Services

Should SEI’s 600 MW Hyperscaler Deal and $1.3 Billion Notes Shape Solaris Energy Infrastructure Investors’ Plans?

In early May 2026, Solaris Energy Infrastructure’s subsidiary completed the pricing of US$1.30 billion of 6.375% senior unsecured notes due 2031, intended to refinance existing borrowings, cover fees and expenses, and support general corporate purposes including growth capital expenditures. This financing followed a strong first quarter 2026, when Solaris reported sharply higher revenue and net income and secured a new 10-year agreement to supply over 600 MW of power capacity and...
NYSE:TDG
NYSE:TDGAerospace & Defense

A Look At TransDigm Group’s Valuation After Recent Share Price Gains

Event context and recent stock performance TransDigm Group (TDG) stock has been on the move recently, with a roughly 7% gain over the past week. This adds to a month-long rise of about 6%, even as the past 3 months show a 3% decline. See our latest analysis for TransDigm Group. At a share price of $1,241.98, TransDigm Group’s recent 7 day and 30 day share price returns contrast with its weaker year to date move. The 3 year total shareholder return of 82.33% and 5 year total shareholder return...
NasdaqGS:BYND
NasdaqGS:BYNDFood

Assessing Beyond Meat (BYND) Valuation After Narrowing Q1 Losses And Softer Sales

Q1 results and new shelf registration Beyond Meat (BYND) has drawn fresh attention after reporting first quarter 2026 results, which showed a reduced net loss alongside lower sales. This was followed shortly by a US$10.4 million shelf registration tied to an employee stock ownership plan. See our latest analysis for Beyond Meat. The stock has moved sharply around the Q1 update and ESOP shelf filing, with a 30-day share price return of 53.93% contrasting with a 1-year total shareholder return...
NasdaqGS:AMKR
NasdaqGS:AMKRSemiconductor

A Look At Amkor Technology (AMKR) Valuation After Record Q1 2026 Results Buyback And New Leveraged ETFs

Amkor Technology (AMKR) is back in focus after reporting record Q1 2026 results, issuing upbeat Q2 guidance, and pairing a new share buyback with fresh leveraged ETFs tied to its stock. See our latest analysis for Amkor Technology. The latest earnings beat, upbeat Q2 guidance and fresh leveraged ETFs have come alongside sharp share price moves, with a 51.76% 1 month share price return and a 68.38% year to date share price return. The 1 year total shareholder return of 306.25% and 5 year total...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Should RVMD’s Wider Losses and Daraxonrasib Progress Require Action From Revolution Medicines (RVMD) Investors?

In the past week, Revolution Medicines reported first-quarter 2026 results showing a wider net loss of about US$453.82 million and basic and diluted losses per share of US$2.29, alongside updated 2026 expense guidance reflecting higher research, development and commercial preparation spending. At the same time, the company highlighted late-stage pancreatic cancer data for lead candidate daraxonrasib and progress toward global regulatory submissions, sharpening the focus on how its expanding...
NYSE:NU
NYSE:NUBanks

Is Nu Holdings (NU) Still Attractive After Recent Pullback And Strong Three Year Run?

Wondering if Nu Holdings is still good value at around US$14.26, or if the easy gains are already behind it? This overview sets you up to judge the stock price with a clear, structured lens. The stock has returned 11.4% over the last year and a very large 3 year gain, even as the year to date move sits at a 16.2% decline, which can change how the market views both its growth potential and risk. Recent headlines have focused on Nu Holdings as a large listed Latin American digital bank, often...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia Pharmaceuticals (AUPH) Q1 EPS Of US$0.26 Tests Bullish Margin Narratives

Aurinia Pharmaceuticals (AUPH) opened Q1 2026 with total revenue of US$77.7 million, basic EPS of US$0.26, and trailing 12 month EPS of US$2.25, following a year in which earnings grew very sharply and the company moved to a 100% net margin. The company has seen quarterly revenue move from US$59.9 million in Q4 2024 to US$62.5 million in Q1 2025 and then to US$77.7 million in Q1 2026, while basic EPS has shifted over the same period from US$0.01 to US$0.17 and then to US$0.26. This has set up...
NYSE:DE
NYSE:DEMachinery

Deere Tests Brand Reach With Every Man Jack Grooming Tie Up

Deere (NYSE:DE) has partnered with Every Man Jack to launch a co branded grooming line. The limited edition products bring the John Deere brand into the consumer personal care market for the first time. The collection is available exclusively at Walmart, targeting a broad retail audience. For a company known primarily for agricultural and construction equipment, this move pulls the John Deere brand into a very different aisle. Deere already sits at the intersection of farming, construction,...
NasdaqGS:CALM
NasdaqGS:CALMFood

Assessing Cal-Maine Foods (CALM) Valuation As Tight Egg Supply Supports Pricing Power

Why tight egg supply is back in focus for Cal-Maine Foods (CALM) Recent commentary points to tight egg supply and steady consumer demand supporting Cal-Maine Foods (CALM), with pricing power, margins and industry consolidation drawing fresh attention to how the stock reflects these conditions. See our latest analysis for Cal-Maine Foods. At a share price of US$75.74, CALM has seen a 90 day share price return of 8.23% decline and a 1 year total shareholder return of 12.14% decline, even though...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Zoetis Resets Outlook As U.S. Pet Weakness Pressures Valuation And Growth

Zoetis (NYSE:ZTS) has cut its full year guidance after a sharp downturn in its U.S. companion animal business. Management points to higher price sensitivity among pet owners, fewer veterinary visits, and more generic competition as key pressures. The company is refocusing on integrated solutions, tighter cost controls, and operational efficiency as part of a broad reset. For investors, the reset lands on top of a steep share price pullback. Zoetis now trades at $87.31, with the stock down...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Is It Too Late To Consider Krystal Biotech (KRYS) After Its Strong Share Price Run?

For investors wondering if Krystal Biotech at around US$296.70 is still offering value or if the easy gains are behind it, this article walks through what the current price may be implying. The stock has shown strong share price moves, with returns of 13.1% over 7 days, 12.4% over 30 days, 20.2% year to date, 116.3% over the last year, 228.5% over 3 years, and 374.4% over 5 years. These price moves sit against a backdrop of ongoing attention on Krystal Biotech's position in the...